BIONANO GENOMICS DL-,0001 Forum: Community User: Shruikan

Gute Nacht BNGO-GANG.

Prost John und Grüße an den Rest .

https://www.youtube.com/watch?v=J06yQb4lbPk

Und dazu noch einen Song! Aller guten Dinge sind 3. RIP Lemmy - we don´t forget u! --->

Ich trink gerade auch einen. Schmeckt viel besser ohne die beschissenen Klimpstengel. Prost Uwe.

Sowas macht uns nur noch stärker. Stimmt´s Marco?

Zur Feier das Tages trinke ich rot 🍷.

Und wieder ein roter Tag,. Da müssen wir jetzt durch💪🏿. John und Marco , ich hoffe ihr habt euch noch im Griff? Stay strong.

Mach endlich das Gap zu!!!

https://www.youtube.com/watch?v=d0ZuRK7Vg1U

Heute ist irgendwie bei mir Lemmy-Tag! --->

Für die 2.0 Version sicher auch gut

Vor allem im Commercial Bereich. Da hatte man bislang Nachholbedarf.

Na für mehr Wachstum braucht es auch entsprechende Strukturen. Macht schon Sinn ;)

Immer mehr Leute die bezahlt werden müssen🤔

SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), developer of the Saphyr ® system that uses optical genome mapping (OGM) for the detection and analysis of structural variants (SVs), today announced that the following individuals have joined the Company’s commercial leadership team to help accelerate the global growth of Saphyr and bolster customer support: Amanda Lettmann, Vice President of Global Customer Experience, Amanda Hernandez, Vice President of Global Sales Training and Development, Justin Leighton, Vice President and General Manager, Lineagen, and Bob Hertsenberg, North America Sales Director. “We are very impressed with the quality of talent we have recruited into our organization,” said Jason Priar, Chief Commercial Officer of Bionano Genomics. “Our Saphyr system and Lineagen’s menu of diagnostic assays are leading solutions in the genomics market and we believe having this team of experienced leaders to support the adoption of both is an outstanding combination. We look forward to the contributions of these individuals to an already strong and passionate culture at Bionano, now and for many years to come.” Amanda Lettmann joins Bionano after holding global enterprise leadership positions at Dexcom, Adobe Systems and Dell/EMC. With her expertise in customer experience operations, business and digital transformation, and omnichannel engagement strategy and contributing to these companies becoming global leaders at scale, she will help lead Bionano’s global care, solutions and experiences teams to focus on customer innovation and centricity across the Company. Amanda Hernandez has over 15 years of experience selling multiple products and services within the pharmaceutical and medical diagnostics industries, most recently at Progenity. A Registered Nurse by training, she has exceled at connecting the right pieces in the commercial process to help create successful outcomes. Amanda is an accomplished leader who helps sales teams improve their selling skills to take their performance to the next level. Justin Leighton, a veteran in the genetics diagnostic testing industry, joins Bionano’s Lineagen business, which focuses on clinical testing in pediatrics. He is a commercial leader in the industry with a diverse background in marketing, operations, IT and commercial matters, most recently at PerkinElmer. Justin has P&L responsibility for Lineagen and will play a key role in helping Bionano work towards its goals in clinical applications. Bob Hertsenberg, a seasoned leader with sales leadership experience at HemoSonics, Cardio Dx and LipoScience, will focus on creating dynamic cross-functional teams to drive top-line revenue growth. Bob has built successful sales teams to drive sales revenue, but more importantly, to provide high levels of care for the patients and clients they serve. He will leverage his previous sales leadership experiences in the medical device and diagnostic industries and work to create a culture of innovation and ownership in the North American sales team. “I am delighted to have Amanda, Amanda, Justin and Bob join the Bionano Genomics commercial team,” stated Erik Holmlin, PhD, CEO of Bionano Genomics. “We believe their combined years of experience in the life sciences and genomics space can add tremendous value to our business and future, as well as help to revolutionize the industry